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Abstract: Statins are lipid-lowing medications shown to reduce cardiovascular events and are recommended for specific patient populations at elevated risk of atherosclerotic cardiovascular disease
(ASCVD). Despite the demonstrated efficacy of statins for reducing ASCVD risk, and guidance on
which populations should receive statin therapy, a substantial portion of eligible patients are not
prescribed statin therapy. Pharmacists have attempted to increase the number of eligible patients
receiving appropriate statin therapy through a variety of interventions and across several clinical
settings. In this article, we highlight multiple studies evaluating the effectiveness of pharmacist-led
interventions to improve statin use. A total of seven studies were selected for this narrative review,
demonstrating the effectiveness and barriers of different statin-initiation programs delivered by pharmacists to increase statin use in eligible patients. Among the interventions assessed, a combination of
provider communicating and statin prescribing through collaborative drug therapy management
(CDTM) appear to the be the most useful at increasing statin use. Pharmacists can significantly
improve statin use rates among eligible patients through multiple intervention types and across
different clinical settings. Further studies should evaluate continued statin adherence and clinical
outcomes among patients served by pharmacists.
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1. Introduction

Academic Editors: Jennifer L. Rodis

Cardiovascular disease (CVD) remains the leading cause of death in the world [1].
In the United States, deaths due to CVD increased by nearly 5% from 2019 to 2020 [2].
The top two contributors to CVD mortality are coronary heart disease and stroke [1].
Prevalence of CVD increases with age, affects a greater proportion of men than women, and
is more common in certain race/ethnicity groups such as non-Hispanic black patients [1].
Interventions to reduce the risk of CVD are multifactorial and include non-pharmacologic
lifestyle changes and medications to treat modifiable major cardiovascular risk factors such
as tobacco use, hypertension, diabetes mellitus (DM), and dyslipidemia [3,4].
Among the medications used to treat dyslipidemia, the HMG-CoA reductase inhibitor
class of medications (or statins), are recommended as first-line agents in patients with an
elevated risk of atherosclerotic cardiovascular disease (ASCVD) [3]. In 2013, updated United
States guidelines for reducing cholesterol and ASCVD risk identified four statin benefit
groups in which treatment with a statin medication is recommended to reduce primary or
secondary ASCVD events [3]. These four statin benefit groups include: (1) patients with
clinical ASCVD; (2) severe hypercholesterolemia; (3) patients with DM age 40–75 years;
(4) patients without DM age 40–75 years, but with an elevated 10-year ASCVD risk. Despite
clearly defined populations likely to benefit from statin therapy, the proportion of eligible
patients receiving guideline recommended statin therapy is sub-optimal. In a study by
Tong et al., statin use patterns were assessed among 223,289 patients from 45 clinical
sites within 8 U.S. states following the publication of the 2013 ACC/AHA cholesterol
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guidelines [5]. While statistically significant improvements in the proportion of ASCVD
patients prescribed high-intensity statin in the 2-year period following the 2013 cholesterol
guideline were reported, only 20.5% of patients with ASCVD were prescribed a highintensity statin. Similarly, less than half (44.9%) of patients aged 40–75 years with DM were
prescribed any intensity of statin 2 years after the 2013 cholesterol guideline publication [5].
How best to address this gap of appropriate statin therapy use in the recommended
benefit groups remains unclear. Currently, outcome measures related to statin use are
used by several healthcare organizations, including the Centers for Medicare and Medicaid
Services (CMS), National Committee for Quality Assurance (NCQA), and the Pharmacy
Quality Alliance (PQA) to encourage effective treatment with statins in two patient populations: (1) statin use in patients with persons with cardiovascular disease (SPC); (2) statin use
in persons with DM (SUPD) [6–8]. Performance on these and other healthcare measures can
be used to evaluate health plans and may be linked with financial incentives [9]. As more
health systems and healthcare payers transition from fee-for-service to a value-based payment model, financial reimbursement will be tied to health systems’ success in achieving
clinical outcome metrics and best practice utilization [9]. Clinical pharmacist’s interventions
have been associated with improved clinical outcomes related to cardiovascular risk factors,
adherence to chronic medication therapy, and improved population health metrics [10–12].
Given their success with improving medication use and disease control, health systems are
utilizing clinical pharmacists to improve statin use measures in diverse ways.
In this narrative review, we highlight multiple pharmacist-led interventions aimed
at improving statin use among different patient populations and across various clinical
settings. The goal of this article is to identify published articles assessing pharmacistled interventions to increase the use of statins and discuss the potential advantages and
disadvantages of each intervention.
2. Materials and Methods
Literature Review
For this narrative review, our intent was not to conduct a comprehensive literature
review of all published data evaluating pharmacist-led initiatives to improve statin use as
would be utilized by a systematic review. Instead, we sought to provide an overview of
published literature and highlight select studies showcasing various pharmacist-led statin
initiation programs and to discuss the strengths and weaknesses of each.
A literature search was conducted in May 2021 across several databases (PubMed,
CINAHL Plus, ScienceDirect). Keywords related to, “statin”, “statins”, “statin-initiation”,
“pharmacist”, or “pharmacists” were used to identify articles which evaluated change in
statin use among a population of statin non-users as a result of a pharmacist-led intervention. Since the statin use measures (SUPD, SPC) are most commonly used by healthcare organizations (Table 1), we included studies evaluating outcomes in patients aged
40–75 years with DM, or patients with cardiovascular disease, consistent with guideline
recommendations. Articles reporting primary outcomes such as change in lipid parameters
or statin adherence were not included. Citations from included articles were also evaluated
for inclusion.
Potential articles were independently reviewed by each author for inclusion based on
the previously mentioned criteria. A total of 7 articles were selected and agreed upon by all
authors after group discussion. These articles were selected based on their pharmacist-led
statin initiation interventions across various clinical settings.
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Table 1. Inclusion and exclusion criteria for statin use measures by organization.
Statin Use in Persons with Diabetes (SUPD)

CMS [6]

HEDIS [8]

PQA [7]

Inclusion criteria

Exclusion criteria a

Age 40–75 years old who were dispensed
at least two diabetes medication fills

Hospice enrollment
ESRD

Age 40–75 years, diagnosed with diabetes
or have at least 2 refills of a
diabetes medication

Cardiovascular disease
ESRD
Cirrhosis
SAMS
Pregnancy
Palliative care

Age 40 to 75 years who were dispensed a
medication for diabetes

Hospice enrollment
ESRD
Liver disease
SAMS
Pregnancy
Pre-diabetes
PCOS

Statin Therapy for Patients with Cardiovascular Disease (SPC)

CMS [6]

Males aged 21–75 years; females
40–75 years with ASCVD and were
dispensed at least one high or
moderate-intensity statin medication

ESRD
Cirrhosis
SAMS
Pregnancy

HEDIS [8]

Males aged 21–75 years; females
40–75 years of age who have clinical
ASCVD and who received statin therapy

Hospice enrollment

a

Select exclusion criteria listed; ASCVD = Atherosclerotic Cardiovascular Disease; CMS = Centers for Medicare
and Medicaid Services; ESRD = End-Stage Renal Disease; HEDIS = Healthcare Effectiveness Data and Information
Set; PCOS = Polycystic Ovarian Syndrome; PQA = Pharmacy Quality Alliance; SAMS = Myalgia, myositis,
myopathy, or rhabdomyolysis.

3. Results
Descriptions of the seven trials are presented below and in Table 2. Discussion of
articles are presented by practice setting: post-hospital discharge; community pharmacy
and outpatient primary care settings.
Table 2. Selected articles describing pharmacist-led statin initiation outcomes.
Study

Hilleman et al. [13]

Clinical Setting

Post-hospital
discharge

Study Population

Patients
discharged from
hospital following
admission to
coronary care unit
for CHD
Control (n = 303)
Intervention
(n = 309)

Pharmacist
Intervention to
Improve Statin Use

Intervention
group—Phone or
mailed
communication to
patient’s PCP
regarding statin
therapy
Control group—no
pharmacist
intervention

Study
Duration

Results

104 weeks

Proportion of patients
prescribed statin therapy
at week 104
(intervention vs.
control):
72% vs. 43%; p < 0.05
MACE events at week
104 (intervention vs.
control):
Hospitalization for MI
(15% vs. 23%)
Coronary
revascularization (12%
vs. 21%)
Cardiovascular
mortality (9% vs. 12%)
p < 0.05 for all MACE
outcomes
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Table 2. Cont.
Clinical Setting

Study Population

Pharmacist
Intervention to
Improve Statin Use

4 community
pharmacies
in Idaho

Patients aged
40–75 years with
T2DM, without
active statin
prescription

Patient outreach and
independent
pharmacist statin
prescribing

Renner et al. [15]

Community
pharmacy

Patients aged
40–75 years with
DM, without active
statin prescription
Control (n = 199)
Intervention
(n = 221)

Vincent et al. [16]

Primary care
clinic with
embedded
clinical
pharmacy
services

Patients aged
40–75 years with
DM, without active
statin prescription,
and upcoming
PCP appointment

Study

Spann et al. [14]

Haby et al. [17]

10 primary care
clinics with
embedded
clinical
pharmacy
services

Study
Duration

Results

3 months

64 eligible patients:
4 patients (6.25%)
initiated statins
2 patients (3.12%)
prescribed statin from
Pharmacists

Intervention
group—Phone and fax
messages to patient’s
PCP to initiate statin
Control—no
pharmacist
intervention

3 months

Proportion of patients
prescribed statin therapy
(Intervention vs.
control):
20.8% vs. 8.5%; p < 0.001
Dispensed statin
prescriptions
(intervention vs. control)
15.4% vs. 7.5%; p = 0.015

Pharmacist notifies
PCP of patient
eligibility prior to
appointment

3 months

111 eligible patients:
28.8% of patients
prescribed statin

3 months

245 eligible patients:
40% agreed to
pharmacistrecommended statin
therapy
Percent of patients
agreeing to statin by
intervention type:
Coordinating with
PCP = 53.3%
Direct patient
outreach = 36.0%

Patients aged
21–75 years with
diagnosis of
ASCVD not
receiving moderate
or high-intensity
statin (n = 307)

Direct patient outreach
and pharmacist statin
prescribing
Coordinating with
PCP about statin use
prior to upcoming
patient visit

Single strategy:
Pharmacist notifies
PCP of patient with
upcoming
appointment and
statin eligibility
Dual strategy: Either
the single strategy
above or pharmacist
sends list of eligible
patients to provider to
receive approval to
contact patient and
initiate statin if patient
agrees

8 months

Proportion of patients
prescribed statins
(single strategy vs. dual
strategy)
46% vs. 36%; p = 0.042
Proportion of patients
prescribed statins
(upcoming appointment
vs. list of eligible
patients)
42.9% vs. 31.5%;
p = 0.049

Patient outreach and
pharmacist statin
prescribing through
CDTM or provider
co-signature

11 months

275 eligible patients:
41.8% of patients
prescribed statin

Troska et al. [18]

Embedded and
centrally located
clinical
pharmacists

Patients aged
40–75 years with
DM, without active
statin prescription
Single strategy
(n = 200)
Dual strategy
(n = 200)

Anderson et al.
[19]

Patient- centered
medical home
(PCMH) clinics
with embedded
clinical
pharmacy
services

Patients aged
40–75 years with
DM, without active
statin prescription

ASCVD = Atherosclerotic Cardiovascular Disease; CDTM = Collaborative Drug Therapy Management; CHD =
Coronary Heart Disease; DM = Diabetes Mellitus; MACE = Major Adverse Cardiovascular Events; PCP = Primary
Care Provider; T2DM = Type 2 Diabetes Mellitus.

3.1. Post-Hospital Discharge
One of the earliest trials assessing the effect of pharmacist intervention on statin utilization was by Hillman et al. [13] who evaluated a post-hospital pharmacist-delivered
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intervention which prompted physicians to optimize statins therapies in patients discharged from a university-affiliated teaching hospital. Patients admitted to the coronary
care unit and diagnosed with coronary heart disease were assigned to control (n = 303)
or intervention (n = 309) groups based on admission date. Patients in the control group
received no pharmacist intervention after hospital discharge. In the intervention group,
pharmacists contacted patients’ provider via mailed letters and phone calls with specific
recommendations for statin initiation or optimization based on patients’ lipid values at 2,
8-, 12-, 24-, and 52-weeks post hospital discharge.
Baseline characteristics of the study groups were similar. At hospital discharge, slightly
more patients in the control group were treated with a statin compared to the intervention
group (39% vs. 35%). Both groups had similar rates of prior myocardial infarction (16%).
After 104 weeks, 43% of patients were on statin therapy in the control group versus 72%
of patients in the intervention group. A greater proportion of the intervention group had
low-density lipoprotein cholesterol (LDL-C) values at goal by week 104 compared to the
control group (55% vs. 18%; p < 0.05). Additionally, patients in the intervention group
had significantly lower clinical events (recurrent myocardial infarction, hospitalization for
myocardial ischemia, coronary revascularization, percutaneous coronary intervention, and
cardiovascular mortality) when compared with the control group. In patients hospitalized
for coronary heart disease, a pharmacist-led intervention after hospital discharge significantly improved statin-use rates and was associated with reduced cardiovascular events
over a 2-year period.
3.2. Community Pharmacy Setting
A pilot study conducted within 4 community outpatient pharmacies in Idaho evaluated the effectiveness and patient perspectives of a pharmacist statin prescribing service [14].
The service was aimed to improve statin use among patients aged 40–75 years with a diagnosis of type 2 DM, but without an active statin prescription. Patients meeting criteria
were identified using the electronic quality improvement platform for plans and pharmacies (EQuIPP) database. Eligible patients were contacted by pharmacists via phone call
(up to 3 attempts) or by placing a note for pharmacist consultation in the patient’s filled
prescriptions. Patients who agreed to the statin service were scheduled for an in-person
appointment at the pharmacy to complete a baseline liver function test before prescribing
a statin. Following a normal liver function result, pharmacists prescribed and dispensed
statin therapy and notified the patient’s primary care provider (PCP). A “nominal” fee was
required of patients who met with the pharmacist and were prescribed statin to cover the
cost of the liver function test and the pharmacist’s time.
A total of 64 eligible patients were identified from the EQuIPP database, of which 33%
had a statin contraindication, 27% could not be contacted, and 19% of patients refused.
Reasons for patient refusal were assessed and included the out-of-pocket cost, preference
for prescriptions to come from their primary care provider, and not understanding the
purpose of a statin. Only 6 patients (9.4%) agreed to the pharmacist service and a total of
4 patients (6.2%) were prescribed a statin; 2 patients (50%) received a statin prescription
from pharmacists, while the other 2 patients requested a statin prescription from their
PCP due to delayed liver function results. Although the effectiveness of this pharmacistled statin prescribing service was low, it may serve as a template for other community
pharmacies looking to increase statin use in the eligible DM population. The fee for the
liver function testing and pharmacist service may be a barrier for engaging patients and
thus alternative payment options for clinical pharmacist services are warranted.
Renner et al. [15] assessed the effectiveness of a pharmacist-led intervention in a community pharmacy setting to initiate statins in patients with DM aged 40–75 years, without
an active statin prescription. Patients were randomized to receive the pharmacist intervention or no intervention (control). In the intervention group pharmacists contacted patients’
PCP via phone and up to two follow-up fax messages requesting a statin prescription.
Reasons for provider refusal were also documented.
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The control group had more males (51.7% vs. 47%) when compared to the intervention
group. Both groups had a mean age of 66 years. After 3 months, a greater proportion of
patients in the intervention group were initiated on statins versus patients in the control
group (20.8% vs. 8.5%; p < 0.001). Approximately 70% of statin prescriptions were received
after the initial phone or first fax message. The number of statins dispensed was significantly
higher with the pharmacist intervention compared to control (15.4% versus 7.5%; p = 0.015).
The top reasons for provider refusal of statin initiation were prior statin intolerance (23.3%),
and PCP preferred to see the patient before initiating a statin (20.8%). This study shows
that a somewhat straightforward pharmacist intervention of messaging providers led
to greater statin initiation and dispensed prescription rates among patients with DM.
Pharmacist access to such data is essential in determining medication gaps in therapy in
order to intervene.
3.3. Outpatient Primary Care Clinics
In an outpatient primary care clinic, Vincent et al. [16] assessed the impact of a pharmacist statin-initiation program in patients with DM. The study assessed the percentage
of patients prescribed statin therapy before and 3 months after the statin program was
initiated. The pharmacist statin-initiation program utilized an electronic medical record
(EMR) report to identify patients aged 40 to 75 years of age with DM, and an upcoming
PCP appointment within the next 3 months. This report also identified which patients
had an active statin prescription listed in the EMR medication list. The pharmacist intervention to improve statin utilization included recommending statins to providers through
face-to-face communication, or EMR messaging. If the physician accepted the pharmacist’s
recommendation, statin initiation could be facilitated by the PCP or pharmacist.
At baseline, a total of 454 patients with DM were identified with the EMR report; most
patients (75.6%) had an active prescription for statin therapy. Baseline characteristics of the
total study population included a mean age of 58 years, nearly 60% female, 76.4% African
American, and 32% had ASCVD. After 3 months, the percentage of patients with an active statin prescription increased to 82.6% (p < 0.0001 compared to baseline). Among the
111 patients (24.4%) without an active statin prescription at baseline, pharmacists made a
total of 61 recommendations, 90.2% were accepted by physicians, but only 32 recommendations (52.5%) to initiate statin therapy were implemented, thus only 28.8% of patients not
receiving statin therapy at baseline-initiated treatment during the 3-month study period.
Notably, 23 out of 61 pharmacist recommendations (37.7%) were deferred by the PCP until
a future appointment. In total, recommending interventions to be carried out by primary
care physicians during outpatient appointments may not be an ideal way to increase statin
initiation among recommended populations.
Haby et al. [17] investigated a population health intervention delivered by clinical
pharmacists across 10 primary care clinics in Washington to increase appropriate statin
use among patients aged 21–75 years with a diagnosis of ASCVD. A report of patients
with ASCVD was generated from the EMR. Identified patients were then screened for
eligibility by pharmacy students and residents, followed by pharmacist review to ultimately
determine statin eligibility. Patients with documented statin intolerance or an erroneous
ASCVD diagnosis were excluded, and their EMR was updated accordingly by pharmacists.
Remaining eligible patients were stratified to two pharmacist intervention types based
on the date of future PCP appointment. For patients with an appointment within the
next 2 months, pharmacists coordinated with their PCP to discuss statin initiation at that
visit. Patients without an appointment in the next 2 months were directly contacted by
pharmacists to verify past medical history and discuss statin treatment. Pharmacists could
then directly prescribe appropriate statin therapy through a health system protocol.
A total of 510 patients were screened for statin appropriateness; however, pharmacist
intervention was attempted for 307 patients (60.2%). After revising the EMR of 62 patients, 245 patients remained eligible for pharmacist intervention. Most patients (76%)
were contacted through direct patient outreach. Overall, 98 patients accepted pharmacists’
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recommendations for statin initiation (40%). Evaluating statin initiation rates by intervention found the highest success with PCP clinic coordination (53.3%), compared to direct
outreach (36%). Among patients who did not initiate statin therapy, 32% could not be
reached and 27% declined. From this population health study, it appears that direct patient
outreach and independent pharmacist statin prescribing are effective ways to increase
appropriate statin use in high-risk patients, although less successful than coordinated
efforts with patients’ PCP.
Two pharmacist-led interventions (upcoming appointment and dual-strategy) to initiate statins in patients with type 2 DM age 40 to 75 years was assessed by Troska et al. [18].
The upcoming appointment intervention utilized pharmacists embedded within the clinic
to identify eligible patients with an upcoming PCP visit within the next 7 days. The
electronic health record specifically identified patients aged 40–75, diagnosed with type
2 DM, currently not receiving statin therapy and with no diagnosis of ASCVD. Pharmacists documented their recommendation for statin therapy in an EMR and forwarded the
recommendation to the patient’s PCP, in addition to adding a note about statin eligibility
to the PCP’s schedule. The dual-strategy intervention method utilized centrally located
pharmacists to recommend statin therapy using the upcoming appointment approach,
or via a second intervention (prospective panel approach) consisting of sending a list
of eligible patients without upcoming appointments to PCPs. Providers reviewed this
list and indicated which patients could be contacted and imitated on statin therapy by
the pharmacist.
A random sample of 400 patients (n = 200 from each intervention strategy) were
chosen for analysis of the primary endpoint. Patients in the dual-strategy cohort were
older (61.2 vs. 58.1 years) and had a higher 10-year ASCVD risk (19.4% vs. 15.6%) compared to the upcoming appointment cohort. Most patients (55.5%) in the dual-strategy
cohort were recommended statin therapy by the upcoming appointment approach. Over
an 8-month study period, statin initiation was higher using the upcoming appointment
method compared to the dual strategy method (46% vs. 36%; p = 0.042). Compared to the
prospective panel approach, the upcoming appointment approach resulted in significantly
greater statin prescribing rates (31.5% vs. 42.9%; p = 0.049). Among this cohort of 400
patients, statin therapy was not initiated in 59.5%, most commonly because statin therapy
was not discussed at the PCP visit, or the patient declined. This study is the first to assess
the effectiveness of two different pharmacist statin initiation interventions, which supports
previous findings that informing physicians about statin eligibility prior to an upcoming
patient appointment resulted in a higher percentage of statin initiation.
A prospective trial by Anderson et al. [19] assessed the effectiveness of clinical pharmacists embedded within several patient centered medical home (PCMH) clinics to improve
the statin use in persons with DM (SUPD) measure among a managed care population. A
list of patients was received aged 40–75 with at least two medication fills for DM with no
statin prescription. Clinical pharmacists reviewed patient eligibility and contacted patients
who met the SUPD criteria. Clinical pharmacists were able to independently prescribe
statin therapy to patients previously referred for pharmacist management using an existing
collaborative drug therapy management (CDTM) protocol. For patients not already referred
for pharmacist disease management, statin therapy could be prescribed by pharmacists but
required a provider co-signature.
At the baseline, 1022 patients were identified as eligible for the SUPD criteria, but
a majority (79.5%) were excluded due to already receiving statins. A remaining 339 patients were identified during the 11-month study period; mean age was 63 years; mean
glycosylated hemoglobin A1c was 8.0%; and mean ASCVD risk score was 21.7%. After
chart review and contacting 326 patients, only 275 (84.4%) were considered eligible to add
statin therapy. Among these patients, 41.8% were prescribed statin therapy. High-intensity
statin was prescribed in 60.9% of patients. Among patients who were not prescribed statin
therapy, the top reasons were patient refusal (23.3%), patients reportedly out of the country
(17.1%), and unable to reach patients after several phone calls (14.9%). Only six providers
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refused to prescribe a statin, usually due to wanting to see the patient in person to discuss.
A CDTM protocol successfully allowed pharmacists to initiate statin therapy and improve
the SUPD measure within a PCMH; however, a large proportion of patients identified
as not meeting the measure were in fact prescribed statin therapy. Significant time and
effort are needed to refine lists generated by health plans to identify patients not receiving
recommended treatment.
4. Discussion
From our review, several types of pharmacist-led interventions significantly increase
statin prescriptions across a variety of clinical settings. The most common types of interventions studied include physician prompting by the pharmacist via messaging or
direct-patient contact with pharmacist prescribing. Simply notifying providers that a patient with an upcoming appointment is eligible for statin therapy was somewhat successful
in initiating statin therapy, as described by Vincent et al. [16]. Two trials evaluated two
different types of pharmacy interventions, direct-patient outreach versus coordinating with
providers about statin eligibility prior to an upcoming patient appointment [17,18] each
reporting a statistically greater proportion of patients prescribed statin therapy with the
provider coordination intervention vs. the direct-patient outreach intervention. However,
Anderson et al. [19] reported somewhat similar success with a direct-patient outreach
intervention which allowed pharmacists to prescribe statins in consenting patients via
a CDTM protocol. In each of these studies, pharmacists were to some degree already
implemented in these clinical sites, suggesting a positive provider-pharmacist relationship
may have already been formed. Comparatively, two trials from community pharmacy
settings [14,15] reported a positive impact on improving statin prescriptions in eligible
patients, but had lower success rates than other trials, even with independent statin prescribing privileges [14]. This finding could be a result of no established pharmacist-provider
relationship. In a trial by Renner et al., a greater proportion of patients were prescribed
statin therapy as a result of pharmacist intervention versus no-intervention, yet only approximately 1 out of 5 eligible patients was prescribed a statin by their provider [15]. In
a trial by Spann et al., pharmacists could independently prescribe statin therapy to consenting patients, yet only 2 patients received a statin prescription from a pharmacist [14].
By far the most successful intervention was seen in the study by Hileman et al., which
showed that pharmacist messaging to providers resulted in significant improvements in
patients prescribed statin therapy, achieving LDL-C goals, and seemed to reduce several
cardiovascular outcomes over a 2-year follow-up period [13]. Potential reasons for such
high success reported in this trial may be due to the academic hospital setting, where a more
collaborative and patient-centered culture exists, the longer study period of 2 years, or that
the study population was at high risk given that they were admitted to the coronary care
unit. Subsequent cost-analysis of this trial evaluated total cost of care for the intervention
and control groups [20]. The total cost of care included pharmacist’s salary, materials for
messaging providers, costs associated with clinic and laboratory tests, as well as the costs
of subsequent cardiovascular events. Across the 2-year study period, total costs per patient
were lower in the intervention group compared to the control group (USD $3474 vs. USD
$5747), resulting in an estimated savings of $1394 per patient. This cost savings was driven
by reduced costs associated with subsequent cardiovascular events.
The first step in implementing any program aimed to increase statin prescriptions is
obtaining reliable data on eligible patients. Several studies demonstrated that among the
reportedly eligible patients, a significant number were excluded due to already receiving
statin therapy or because of an exclusion (i.e., statin intolerance). In the study by Haby et al.,
among the 510 patients initially identified as not meeting the SUPD metric, 16.5% of patients
screened were excluded as they were deemed not appropriate due to inclusion or exclusion
metric reporting error, recent discontinuation of statin by patient or provider, or the patient
had not seen their provider in over 1-year [17]. In the trial by Anderson et al., 79% of
patients initially identified as not meeting the SUPD measure were excluded because they
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were already prescribed a statin [19]. Utilizing other non-clinical staff such as pharmacy
technicians or pharmacy students may be an effective way to review patient charts for
eligibility to maximize clinical pharmacists’ time delivering patient care.
In trials where pharmacists directly outreached to patients about statin eligibility, a
large proportion of patients declined [14,18,19]. Reported reasons for patients declining
included that they were not aware of the benefits or felt they did not need the statin [14].
This finding suggests that pharmacists who outreach to patients will need to be able to
adequately describe the benefits and risks of statin therapy. A 2019 systematic review
of interventions to increase statin prescribing in primary prevention populations found
that interventions aimed at educating patients were more successful at increasing statinprescription rates compared to physician education and decision-support interventions [21].
Several organizations provide patient-friendly material on statin treatment which may be
useful in describing the real vs. perceived benefits and adverse effects [22–24].
Lastly, once statins have been prescribed there exists additional roles for pharmacists
to ensure patients continue to take them. In addition to the SUPD and SPC measure,
several agencies also evaluate the portion of days covered (PDC) statin measure as well.
Pharmacists have demonstrated significant abilities to improve adherence to statin therapy
through a variety of methods [25]. A randomized cluster trial evaluated the effect of a multicomponent, individualized behavioral intervention delivered remotely by pharmacists on
medication adherence versus no intervention in patients prescribed chronic medication for
hypertension, DM, or dyslipidemia within a large medical group [26]. Over a 12-month
period, medication adherence was 4.7% higher in the intervention group compared to
control, despite no significant improvement in disease control in 1 or more conditions but
was associated with a 38% reduction in emergency department visits. As such, pharmacist
interventions to increase statin prescribing should be tied to individualized interventions
to maintain statin adherence for optimal patient outcomes.
Limitations of our review include potential selection bias as authors were responsible
for selecting included articles for this narrative review, potentially excluding other relevant
work. Additionally, compared to systematic reviews narrative reviews typically do not
assess the quality of included studies [27]. While it may be possible that other relevant
articles were overlooked, we believe our literature search and selection process are sufficient
to provide a broad overview on the topic pharmacist interventions to improve statin
use, as is the intent of narrative reviews [27]. Secondly, all but one article assessed a
primary prevention population with diabetes aged 40–75 years, thus generalizability to
other statin benefit groups may not be applicable. Despite current cholesterol guidelines
recommending statin therapy for patients aged 40–75 years with DM [28], some patients
are not prescribed statin therapy for primary prevention as they or their prescriber believe
their cholesterol values to be controlled [15,17,19]. Given that elevated cholesterol is
associated with increased ASCVD risk, it is not the only factor to consider when determining
whether a patient with DM should receive statin therapy for primary prevention. A recent
meta-analysis assessed the risk of ASCVD events among patients with DM, but without
cardiovascular disease, and LDL-C values of 100 to 159 mg/dL [29]. From the eleven trials
included, statin therapy was associated with a lower risk of composite cardiovascular events
(RR = 0.71; 95% CI, 0.62–0.82) as well as coronary revascularizations and cardiovascular
hospitalizations [29]. This adds to growing data suggesting statins are effective in reducing
ASCVD events in primary prevention patients with mildly elevated LDL-C.
5. Conclusions
Multiple pharmacist-led interventions have led to increased statin use and are likely
to improve statin-related outcome metrics; however, a substantial number of patients do
not receive guideline recommended statin therapy. The most effective interventions to
increase statin use appear to include pharmacist prompting of providers in settings where
an established relationship exists between provider and pharmacist.
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Barriers to increasing statin use in high-risk patient populations include erroneous
patient eligibility data and patient’s declining statin therapy. Further studies assessing
interventions to resolve patient and provider barriers to increasing statin use in high-risk
groups is needed to reduce the number of patients without statin treatment and lower
the global burden of CVD. Health systems looking to improve metrics related to statin
use should select an intervention that best aligns with their patient population, clinical
pharmacy workforce, and health system structure. Assessing avoided ASCVD events in
patients treated with statin therapy would be an important outcome of future studies.
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